Purdue Pharma Lp patents expiration
1. Adhansia Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(11 years from now) | |
| US10722473 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Jun 28, 2024 |
| New Product(NP) | Feb 27, 2022 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR family patents
2. Butrans patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6264980 | PURDUE PHARMA LP | Transdermal resorption of active substances from supercooled masses of levulic acid |
Dec, 2015
(8 years ago) | |
| US6344211 | PURDUE PHARMA LP | Transdermal absorption of active substances from subcooled melts |
Dec, 2015
(8 years ago) | |
| US9642850 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
| USRE41571 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
| USRE41408 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorpine |
Sep, 2017
(6 years ago) | |
| USRE41489 | PURDUE PHARMA LP | Method of providing sustained analgesia with buprenorphine |
Sep, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-250) | Oct 13, 2020 |
| New Dosage Form(NDF) | Jun 30, 2013 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 June, 2010
Treatment: The management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time; Management of pain severe enough to require dail...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
BUTRANS family patents
3. Chirocaine patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5708011 | PURDUE PHARMA LP | Use of levobupivacaine in a patient having depressed myocardial contractility |
Oct, 2014
(9 years ago) | |
Drugs and Companies using LEVOBUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 August, 1999
Treatment: Method of use of levobupivacaine
Dosage: INJECTABLE;INJECTION
CHIROCAINE family patents
4. Hysingla Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6488963 | PURDUE PHARMA LP | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(6 years ago) | |
| US9572804 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9023401 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9669023 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9669024 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9056052 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9198863 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9205056 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9517236 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9060940 | PURDUE PHARMA LP | Controlled release hydrocodone |
Oct, 2020
(3 years ago) | |
| US9289391 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2020
(3 years ago) | |
| US9675611 | PURDUE PHARMA LP | Methods of providing analgesia |
Oct, 2020
(3 years ago) | |
| US9682077 | PURDUE PHARMA LP | Methods of providing analgesia |
Oct, 2020
(3 years ago) | |
| US6733783 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8647667 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8551520 | PURDUE PHARMA LP | Controlled release hydrocodone |
Oct, 2021
(2 years ago) | |
| US8361499 | PURDUE PHARMA LP | Controlled release hydrocodone formulations |
Oct, 2021
(2 years ago) | |
| US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US11844865 | PURDUE PHARMA LP | Abuse-proofed oral dosage form |
Feb, 2025
(9 months from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER family patents
5. Oxycontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(11 months from now) | |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(11 months from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508042 | PURDUE PHARMA LP | Controlled release oxycodone compositions |
Apr, 2013
(11 years ago) | |
| US6488963 | PURDUE PHARMA LP | Hot-melt extrudable pharmaceutical formulation |
Jun, 2017
(6 years ago) | |
| US9060976 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US8337888 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 8 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(10 months ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US10675278 | PURDUE PHARMA LP | Crush resistant delayed-release dosage forms |
Nov, 2023
(5 months ago) | |
| US8114383 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Oct, 2024
(5 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(11 months from now) | |
| US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(5 years from now) | |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 December, 1995
Treatment: Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time; Management of pain severe enough to require daily, around-the-clock, long ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN family patents
6. Palladone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6743442 | PURDUE PHARMA LP | Melt-extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US5958452 | PURDUE PHARMA LP | Extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US5965161 | PURDUE PHARMA LP | Extruded multi-particulates |
Nov, 2014
(9 years ago) | |
| US6335033 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6706281 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6589960 | PURDUE PHARMA LP | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 September, 2004
Treatment: Management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time generally weeks to months or lo...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
PALLADONE family patents
7. Targiniq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(11 months from now) | |
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474750 | PURDUE PHARMA LP | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(5 years ago) | |
| US8822487 | PURDUE PHARMA LP | Opioid agonist/opioid antagonist/acetaminophen combinations |
Dec, 2018
(5 years ago) | |
| US9205082 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US6696066 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US6277384 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US8673355 | PURDUE PHARMA LP | Opioid agonist/antagonist combinations |
Dec, 2018
(5 years ago) | |
| US9084729 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9056051 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US8969369 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9511066 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9283216 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9283221 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9168252 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9161937 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9345701 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 11 months ago) | |
| US9555000 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(1 year, 23 days ago) | |
| US8846090 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(1 year, 23 days ago) | |
| US8846091 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(1 year, 23 days ago) | |
| US9907793 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(1 year, 23 days ago) | |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2017 |
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TARGINIQ family patents